Citations

Clear

6273 citation(s) found for "To, Andrew".

Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient: 2016 update—executive summary
DeBlock, Heidi F., Erstad, Brian L. , Gray, Anthony, Jacobi, Judith , Jordan, Ché J., McGee, William T. , McManus, Claire, Meade, Maureen O. , Nix, Sean , Sands, Karen, Pino, Richard M. , Tescher, Ann, Arbour, Richard, Murray, Catherine Friederich, Mehta, Sangeeta , Tescher, Ann N, Murray, Michael J. , Patterson, Andrew J. , Rochwerg, Bram

Mayo Clinic

American Journal of Health-System Pharmacy | January 9, 2017 | Volume: 74 | Issue: 2 | Pages: 76-78

10.2146/ajhp160803 | PMID 28069681 Get It

GAD65 neurological autoimmunity
McKeon, Andrew , Tracy, Jennifer A., McKeon, Andrew

Mayo Clinic

Muscle & Nerve | January 7, 2017 | Volume: 56 | Issue: 1 | Pages: 15-27

10.1002/mus.25565 | PMID 28063151 Get It

ABSTRACT The glutamic acid decarboxylase 65‐kilodalton isoform (GAD65) antibody is a biomarker of autoimmune central nervous system (CNS) disorders and, more commonly, nonneurological autoimmune diseases. Type 1 diabetes, autoimmune thyroid disease, and pernicious anemia are the most frequent GAD65 autoimmune associations. One or more of these disorders coexists in approximately 70% of patients with GAD65 neurological autoimmunity. Neurological phenotypes have CNS localization and include limbic encephalitis, epilepsy, cerebellar ataxia, and stiff‐person syndrome (SPS), among others. Classic SPS is a disorder on the spectrum of CNS hyperexcitability which also includes phenotypes that are either more restricted (stiff‐limb syndrome) or more widespread (progressive encephalomyelitis with rigidity and myoclonus). GAD65 antibody is not highly predictive of a paraneoplastic cause for neurological disorders, but diverse cancer types have been occasionally reported. For all phenotypes, responses to immunotherapy are variable (approximately 50% improve). GAD65 autoimmunity is important to recognize for both coexisting nonneurological autoimmune associations and potential immunotherapy‐response. Muscle Nerve 56 : 15–27, 2017
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
Himelstein, Andrew L., Foster, Jared C. , Khatcheressian, James, Roberts, John D. , Seisler, Drew K., Novotny, Paul J. , Qin, Rui , Grubbs, Stephen S., O’Connor, Tracey L. , Velasco, Mario R. , Weckstein, Douglas, O’Mara, Ann M., Loprinzi, Charles L. , Go, Ronald S. , Shapiro, Charles L.

Mayo Clinic

JAMA | January 5, 2017 | Volume: 317 | Issue: 1 | Pages: 48

10.1001/jama.2016.19425 | PMID 28030702 Get It

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
Walz, Amy L. , Ugolkov, Andrey , Chandra, Sunandana , Kozikowski, Alan P. , Carneiro, Benedito A. , O’Halloran, Thomas V. , Billadeau, Daniel D. , Mazar, Andrew P. , Giles, Francis Joseph

Mayo Clinic

Clinical Cancer Research | January 5, 2017 | Volume: 23 | Issue: 8 | Pages: 1891-1897

10.1158/1078-0432.ccr-15-2240 | PMID 28053024 Get It

Abstract Glycogen synthase kinase-3β (GSK-3β), a serine/threonine protein kinase, is a complex regulator of numerous cellular functions. GSK-3β is a unique kinase which is constitutively active in resting and nonstimulated cells. GSK-3β has been implicated in a wide range of diseases including neurodegeneration, inflammation and fibrosis, noninsulin-dependent diabetes mellitus, and cancer. It is a regulator of NF-κB–mediated survival of cancer cells, which provided a rationale for the development of GSK-3 inhibitors targeting malignant tumors. Recent studies, many of them reported over the past decade, have identified GSK-3β as a potential therapeutic target in more than 15 different types of cancer. Whereas only active GSK-3β is expressed in cancer cell nucleus, aberrant nuclear accumulation of GSK-3β has been identified as a hallmark of cancer cells in malignant tumors of different origin. This review focuses on the preclinical and clinical development of GSK-3 inhibitors and the potential therapeutic impact of targeting GSK-3β in human cancer. Clin Cancer Res; 23(8); 1891–7. ©2017 AACR.
The complex genetics of gait speed: genome-wide meta-analysis approach
Ben-Avraham, Dan, Karasik, David , Verghese, Joe , Lunetta, Kathryn L. , Smith, Jennifer A. , Eicher, John D., Vered, Rotem, Deelen, Joris , Arnold, Alice M. , Buchman, Aron S. , Faul, Jessica D. , Nethander, Maria , Fornage, Myriam , Adams, Hieab H.H. , Matteini, Amy M., Callisaya, Michele L. , Smith, Albert V. , Yu, Lei, Jager, Philip L. De , Evans, Denis A., Guðnason, Vilmundur , Hofman, Albert , Pattie, Alison, Knopman, Davis S., Parimi, Neeta, Bandinelli, Stefania , Beekman, Marian , Gutman, Danielle , Sharvit, Lital , Mooijaart, Simon P. , Liewald, David C. , Houwing‐Duistermaat, Jeanine J. , Ohlsson, Claes , Moed, Matthijs, Hernández, Dena , McWhirter, Rebekah , Thomson, Russell , Tranah, Gregory J. , Uitterlinden, André G. , Weir, David R. , Zhao, Wei , Starr, John M. , Johnson, Andrew D. , Bennett, David A. , Cummings, Steven R. , Deary, Ian J. , Harris, Tamara B., Kardia, Sharon L. R., Mosley, Thomas H. , Srikanth, Velandai , Windham, B. Gwen , Davies, Gail , Evans, Daniel S. , Ferrucci, Luigi , Atzmon, Gil , Bennett, David A. , Turner, Stephen T. , Tanaka, Toshiko , Corley, Janie , Launer, Lenore J. , Verlinden, Vincentius J.A. , Mellström, Dan , Geest, Jos N. van der , Karlsson, Magnus K , Liu, Ching‐Ti , Ikram, M. Arfan , Newman, Anne B. , Walston, Jeremy D , Slagboom, P. Eline , Kiel, Douglas P. , Murabito, Joanne M. , Smith, Jennifer A , Adams, Hieab H H , Smith, Albert V , Ferrucci, Luigi , Ohlsson, Claes , Srikanth, Velandai K

Mayo Clinic

Aging | December 30, 2016 | Volume: 9 | Issue: 1 | Pages: 209-246

10.18632/aging.101151 | PMID 28077804 Get It

Outcomes of Holmium Laser Enucleation of the Prostate in the Re-Treatment Setting
Marien, Tracy , Kadıhasanoğlu, Mustafa , Tangpaitoon, Teerayut , York, Nadya , Blackburne, Andrew T. , Abdul-Muhsin, Haidar , Borofsky, Michael S. , Krambeck, Amy E. , Humphreys, Mitchell R. , Lingeman, James E., Miller, Nicole L. , Miller, Nicole L

Mayo Clinic

Journal of Urology | December 30, 2016 | Volume: 197 | Issue: 6 | Pages: 1517-1522

10.1016/j.juro.2016.12.098 | PMID 28043843 Get It

High‐resolution electrical mapping of porcine gastric slow‐wave propagation from the mucosal surface
Angeli, Timothy R. , Du, Peng , Sathar, Shameer , Asirvatham, S, Farrugia, Gianrico , Windsor, John A. , Cheng, Leo K. , O’Grady, Gregory , Asirvatham, Samuel J. , Paskaranandavadivel, Niranchan , Hall, Andrew , Asirvatham, Samuel J , Angeli-Gordon, Timothy R

Mayo Clinic

Neurogastroenterology & Motility | December 30, 2016 | Volume: 29 | Issue: 5 | Pages: No page available

10.1111/nmo.13010 | PMID 28035728 Get It

AbstractBackgroundGastric motility is coordinated by bioelectrical slow waves, and gastric dysrhythmias are reported in motility disorders. High‐resolution (HR) mapping has advanced the accurate assessment of gastric dysrhythmias, offering promise as a diagnostic technique. However, HR mapping has been restricted to invasive surgical serosal access. This study investigates the feasibility of HR mapping from the gastric mucosal surface.MethodsExperiments were conducted in vivo in 14 weaner pigs. Reference serosal recordings were performed with flexible‐printed‐circuit (FPC) arrays (128‐192 electrodes). Mucosal recordings were performed by two methods: (i) FPC array aligned directly opposite the serosal array, and (ii) cardiac mapping catheter modified for gastric mucosal recordings. Slow‐wave propagation and morphology characteristics were quantified and compared between simultaneous serosal and mucosal recordings.Key ResultsSlow‐wave activity was consistently recorded from the mucosal surface from both electrode arrays. Mucosally recorded slow‐wave propagation was consistent with reference serosal activation pattern, frequency (P≥.3), and velocity (P≥.4). However, mucosally recorded slow‐wave morphology exhibited reduced amplitude (65‐72% reduced, P<.001) and wider downstroke width (18‐31% wider, P≤.02), compared to serosal data. Dysrhythmias were successfully mapped and classified from the mucosal surface, accorded with serosal data, and were consistent with known dysrhythmic mechanisms in the porcine model.Conclusions & InferencesHigh‐resolution gastric electrical mapping was achieved from the mucosal surface, and demonstrated consistent propagation characteristics with serosal data. However, mucosal signal morphology was attenuated, demonstrating necessity for optimized electrode designs and analytical algorithms. This study demonstrates feasibility of endoscopic HR mapping, providing a foundation for advancement of minimally invasive spatiotemporal gastric mapping as a clinical and scientific tool.
Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci
Reid, Brett M. , Teer, Jamie K. , Monteiro, Álvaro N.A. , Chen, Zhihua , Chenevix‐Trench, Georgia , Goode, Ellen L. , Iverson, Edwin S., Lawrenson, Kate , Pearce, Celeste Leigh , Phelan, Catherine M., Ramus, Susan J. , Rossing, Mary Anne, Schildkraut, Joellen M. , Cheng, Jin Q. , Gayther, Simon A. , Sellers, Thomas A. , Bowtell, David D.L. , Permuth, Jennifer B. , Chen, Y. Ann , Tyrer, Jonathan P. , Berchuck, Andrew , Doherty, Jennifer A. , Pharoah, Paul D.P. , Ramus, Susan J , Lawrenson, Kate , Monteiro, Alvaro N , Chenevix-Trench, Georgia , Bowtell, David D

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 29, 2016 | Volume: 26 | Issue: 1 | Pages: 116-125

10.1158/1055-9965.epi-16-0341 | PMID 28035019 Get It

Abstract Background: Genome-wide association studies (GWAS) have identified multiple loci associated with epithelial ovarian cancer (EOC) susceptibility, but further progress requires integration of epidemiology and biology to illuminate true risk loci below genome-wide significance levels (P &lt; 5 × 10−8). Most risk SNPs lie within non–protein-encoding regions, and we hypothesize that long noncoding RNA (lncRNA) genes are enriched at EOC risk regions and represent biologically relevant functional targets. Methods: Using imputed GWAS data from about 18,000 invasive EOC cases and 34,000 controls of European ancestry, the GENCODE (v19) lncRNA database was used to annotate SNPs from 13,442 lncRNAs for permutation-based enrichment analysis. Tumor expression quantitative trait locus (eQTL) analysis was performed for sub-genome-wide regions (1 × 10−5 &gt; P &gt; 5 × 10−8) overlapping lncRNAs. Results: Of 5,294 EOC-associated SNPs (P &lt; 1.0 × 10−5), 1,464 (28%) mapped within 53 unique lncRNAs and an additional 3,484 (66%) SNPs were correlated (r2 &gt; 0.2) with SNPs within 115 lncRNAs. EOC-associated SNPs comprised 130 independent regions, of which 72 (55%) overlapped with lncRNAs, representing a significant enrichment (P = 5.0 × 10−4) that was more pronounced among a subset of 5,401 lncRNAs with active epigenetic regulation in normal ovarian tissue. EOC-associated lncRNAs and their putative promoters and transcription factors were enriched for biologically relevant pathways and eQTL analysis identified five novel putative risk regions with allele-specific effects on lncRNA gene expression. Conclusions: lncRNAs are significantly enriched at EOC risk regions, suggesting a mechanistic role for lncRNAs in driving predisposition to EOC. Impact: lncRNAs represent key candidates for integrative epidemiologic and functional studies. Further research on their biologic role in ovarian cancer is indicated. Cancer Epidemiol Biomarkers Prev; 26(1); 116–25. ©2016 AACR.
Comparison of longterm outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity‐matched cohort
Croome, Kristopher P. , Lee, David D. , Perry, Dana K. , Burns, Justin M. , Nguyen, Justin H. , Taner, C. Burcin , Keaveny, Andrew P. , Croome, Kris P , Lee, David D

Mayo Clinic

Liver Transplantation | December 27, 2016 | Volume: 23 | Issue: 3 | Pages: 342-351

10.1002/lt.24713 | PMID 28027600 Get It

The use of liver grafts from donation after cardiac death (DCD) has been limited due to the increased rate of graft failure, mostly related to ischemic cholangiopathy (IC). It is our hypothesis that longterm outcomes and quality of life (QOL) similar to patients undergoing liver transplantation (LT) with donation after brain death (DBD) can be achieved. Clinical outcomes of all patients undergoing DCD LT (n = 300) between 1998 and 2015 were compared with a propensity score–matched cohort of patients undergoing DBD LT (n = 300). Patients were contacted for a follow‐up questionnaire and short‐form (SF)–12 QOL Survey administration. Median follow‐up was >5 years. Graft survival at 1‐, 3‐, and 5‐years was 83.8%, 75.5%, and 70.1% in the DCD LT group and 88.4%, 80.3%, and 73.9% in the DBD LT group ( P = 0.27). Patient survival at 1‐, 3‐, and 5‐years was 92.3%, 86.1%, and 80.3% in the DCD LT group and 92.3%, 85.1%, and 79.5% in the DBD LT group ( P = 0.81). IC developed in 11.7% and 2% of patients in the DCD LT group and DBD LT group, respectively ( P < 0.001). DCD LT recipients who developed IC had inferior graft survival compared with both the DCD non‐IC group ( P < 0.001) and the DBD LT group ( P < 0.001); no difference in graft survival was observed between the DCD non‐IC group and the DBD LT group ( P = 0.50). Physical and Mental Composite Scores on the SF‐12 QOL questionnaire were similar between the DCD LT and DBD LT groups (44.0 versus 45.4; P = 0.34 and 51.9 versus 52.2; P = 0.83), respectively. Similar longterm survival and QOL scores can be achieved between DCD LT and DBD LT. Prevention of IC in DCD LT yields excellent graft and patient survival with virtually no difference compared with DBD LT. Liver Transplantation 23 342–351 2017 AASLD .
Smokeless Tobacco use among United States Air Force Trainees
Linde, Brittany D. , Ebbert, Jon O. , Schroeder, Darrell R. , Hanson, Andrew C. , Talcott, G. Wayne , Klesges, Robert C. , Schroeder, Darrell

Mayo Clinic

Substance Abuse | December 27, 2016 | Volume: 38 | Issue: 3 | Pages: 278-284

10.1080/08897077.2016.1275924 | PMID 28027011 Get It

Background The prevalence of smokeless tobacco use in the United States Air Force (USAF) exceeds civilian use rates. The prevalence and correlates of smokeless tobacco use were assessed and evaluated in a sample of USAF trainees. Methods We conducted a cross-sectional survey of USAF technical training school personnel at Joint Base San Antonio-Lackland and Fort Sam Houston ( N = 14,810). Survey completion rate was 78%. Logistic regression was used to analyze the associations between demographic variables, tobacco use, and social factors for both regular and infrequent smokeless tobacco (e.g., chewing tobacco, snuff) users. Results Overall, 16% of Airmen had ever used smokeless tobacco and 10% regularly used smokeless tobacco. In multivariate analyses, men had greater odds than women of regular smokeless tobacco use (adjusted odds ratio [OR] = 15.2; 95% confidence interval [CI]: 10.8–21.5) and infrequent smokeless tobacco use (adjusted OR = 4.2; 95% CI: 3.1–5.7). Smokeless tobacco use was associated with participation in high school sports (adjusted OR = 1.9; 95% CI: 1.6–2.3 for regular users; adjusted OR = 1.4; 95% CI: 1.1–1.7 for infrequent users), smoking cigarettes (adjusted OR = 4.3; 95% CI: 3.6–5.1 for regular users; adjusted OR = 4.0; 95% CI: 3.2–5.0 for infrequent users), or living with someone who used smokeless tobacco (adjusted OR = 2.2; 95% CI: 1.9–2.6 for regular users; adjusted OR = 1.4; 95% CI: 1.1–1.7 for infrequent users). Black or African Americans were less likely than whites to be regular (adjusted OR = 0.3; 95% CI: 0.1–0.4) or infrequent (adjusted OR = 0.3; 95% CI: 0.2–0.4) users of smokeless tobacco. Conclusions Smokeless tobacco use among incoming Air Force recruits is common and negatively impacts the Air Force's goal to be tobacco-free. Understanding sociodemographic characteristics perpetuating smokeless tobacco use in the Air Force population can inform the development of health promotion interventions.